Descrizione del progetto DEENESFRITPL Semplificare la diagnostica basata sulle nanotecnologie Gli esami diagnostici costituiscono l’elemento fondamentale delle decisioni sanitarie prese al giorno d’oggi e risultano essenziali per realizzare trattamenti efficaci. Gli strumenti diagnostici devono offrire una capacità analitica ad alta produttività e un’elevata qualità dei dati, oltre a consumare un volume di campione ridotto. Le nanotecnologie offrono la capacità di far progredire ulteriormente la diagnostica molecolare avanzata presso il punto di assistenza. Per affrontare questa esigenza, il progetto Nano4, finanziato dall’UE, ha sviluppato NANO4, una tecnologia diagnostica basata su nanotecnologie che si avvale di nanosonde per rilevare le molecole di DNA e RNA. Il risultato è visibile grazie a un cambiamento di colore, il che rende il dispositivo estremamente intuitivo e agevola un processo decisionale rapido. L’idea è quella di applicare inizialmente NANO4 per la diagnosi della tubercolosi e della leucemia, che rappresentano problemi medici di stampo globale. Mostra l’obiettivo del progetto Nascondi l’obiettivo del progetto Obiettivo There is a need for cost-effective molecular point of care diagnostic tools to provide better healthcare to patients and better agility to our healthcare system. And what about going one step further by extending the limits of molecular diagnostics to the nano-scale?The market needs a rapid and definitive answer at entry level. Needs a diagnostic that is capable of screen directly and simply hundreds of samples with low infrastructure and low-grade people, that can rely on existing peripheral infrastructure like peripheral hospital and microscopy centres.We have developed the nano-technology-based solution NANO4. NANO4 is a fast and user-friendly nano-based diagnostic technology suitable for use at the Point of Need. NANO4 represents a highly specific and sensitive nanotechnology for in vitro molecular diagnostics. It uses gold nano-probes to recognize the complementary DNA/RNA strand and yield a colour output that allows for quick decision making.Molecular diagnosis is a multi-million Euro market and making use of our SME Instrument Phase 1 Feasibility Study, we defined our go-to-market roadmap for our first disruptive products: NANO4 TB for Tuberculosis, and NANO4 CML for Chronic Myeloid Leukaemia, including industrial scale-up and CE mark.We have already established partnerships with distributors in Europe and Brazil, and our technology has been referenced by FIND as a promising new solution for TB diagnosis. We have also established a connection with the World Health Organization, in order to obtain an endorsement as soon as we receive the CE mark.NANO4 was founded in end 2015, and we have raised €200.000 from Business Angels and have already begun our operations to take our products to the market, expecting a Series A at the end of 2018.With the successful conclusion of this project, NANO4 will become one of the few companies in Europe to possess nanotechnology capacities at industrial scale, focused on the life sciences sector. Campo scientifico engineering and technologymaterials engineeringcolorsengineering and technologynanotechnologymedical and health sciencesclinical medicinepneumologytuberculosisengineering and technologymedical engineeringmedical laboratory technologydiagnostic technologiesmedical and health sciencesclinical medicineoncologyleukemia Programma(i) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Argomento(i) EIC-SMEInst-2018-2020 - SME instrument Invito a presentare proposte H2020-EIC-SMEInst-2018-2020 Vedi altri progetti per questo bando Bando secondario H2020-SMEInst-2018-2020-2 Meccanismo di finanziamento SME-2 - SME instrument phase 2 Coordinatore NANO4 GLOBAL LDA Contribution nette de l'UE € 1 420 230,00 Indirizzo Estrada da Granja do Marquês, nº 339, Armazém B 2710-142 Sintra Portogallo Mostra sulla mappa PMI L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione. Sì Regione Continente Área Metropolitana de Lisboa Área Metropolitana de Lisboa Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Collegamenti Contatta l’organizzazione Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 2 028 900,00
